A new experimental treatment using CRISPR gene-editing technology has shown promising results in reducing LDL cholesterol levels by up to 52.5 percent after one year in patients who did not respond to traditional therapies, according to a recent clinical trial. The treatment, named CTX310, works by modifying the ANGPTL3 gene in liver cells, aiming to mimic the effects of natural genetic mutations that are associated with lower cholesterol and triglyceride levels. This approach could offer a novel way to manage lipid disorders, which are major risk factors for heart disease and stroke. LDL cholesterol, often called "bad" cholesterol, can build up in the arteries, forming plaques that contribute to atherosclerosis—a condition that increases the risk of heart attacks and strokes. While lifestyle and dietary changes can help manage LDL levels, some people naturally have genetic variants of the ANGPTL3 gene that lower their cholesterol and triglycerides. These variants have provided scientists with insights into how the ANGPTL3 protein influences lipid metabolism. The protein plays a role in regulating the breakdown of fats in the blood, and reducing its activity can lead to lower levels of harmful lipids. The treatment, developed by researchers at the Cleveland Clinic Coordinating Center for Clinical Research, uses a CRISPR-based method to target the ANGPTL3 gene in liver cells. It includes messenger RNA and guide RNA, packaged in lipid nanoparticles, which are delivered through an intravenous infusion. In the trial, 15 patients with severe lipid disorders who had not responded to conventional treatments received the treatment. After 12 months, four of the patients who received the highest dose saw a 78.6 percent reduction in ANGPTL3 levels, which translated into significant drops in LDL cholesterol and triglyceride levels. No serious side effects were reported in the 14 surviving participants, though one patient died 179 days after treatment, unrelated to the therapy. While the results are encouraging, the researchers note that the trial involved a small number of patients and further studies are needed to confirm the treatment's safety and effectiveness in a broader population. A phase 1b trial is currently underway to test the most effective dose in a larger group of patients. The study highlights the potential of CRISPR-based therapies to mimic beneficial genetic mutations, offering a one-time treatment for individuals with lipid disorders. However, long-term safety and individual variations in response remain areas for further investigation.